Comparison of pixantrone-Based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-Cell lymphoma

Annals of Oncology

Volumn 24, Issue 10, 2013, Pages 2618-2623

  Herbrecht, R ^a   Cernohous, P ^b   Engert, A ^c   Le Gouill, S ^d   Macdonald, D ^e   Machida, C ^b   Myint, H ^b   Saleh, A ^f   Singer, J ^b   Wilhelm, M ^g   van der Jagt, R ^h  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b Cell Therapeutics Inc   (United States)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d HÔTEL DIEU   (France)

^e QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^f SHARP HEALTHCARE   (United States)

^g KLINIKUM NÜRNBERG   (Germany)

^h UNIVERSITY OF OTTAWA   (Canada)

Author keywords

CPOP R; Diffuse large B Cell lymphoma; Doxorubicin; Pixantrone; Randomized clinical trial

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PIXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOKALEMIA; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING;

CPOP-R; DIFFUSE LARGE B-CELL LYMPHOMA; DOXORUBICIN; PIXANTRONE; RANDOMIZED CLINICAL TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HEART FAILURE; HUMANS; ISOQUINOLINES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; STROKE VOLUME; SURVIVAL; SURVIVAL RATE; TOPOISOMERASE II INHIBITORS; TREATMENT OUTCOME; TROPONIN T; VINCRISTINE;

EID: 84884724017     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt289     Document Type: Article

References (12)

1. Fisher RI. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 1997; 40(suppl):S42-S46.
2. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328(14): 1002-1006.
3. Coiffier B, Lepage E, Briere J et al. CHOP Chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346(4): 235-242.
4. Hershman DL, McBride RB, Eisenberger A et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26(19): 3159-3165.
5. Salvatorelli E, Menna P, Paz OG et al. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther 2013; 344(2): 467-478.
6. Pangalis GA, Vassilakopoulos TP, Michalis E et al. A randomized trial comparing intensified CNOP versus CHOP in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44(4): 635-644.
7. Sonneveld P, de Ridder M, van der Lelie H et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non- Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13(10): 2530-2539.
8. Borchmann P, Schnell R, Knippertz R et al. Phase I study of BBR 2778, a new azaanthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 2001; 12(5): 661-667.
9. Borchmann P, Morschhauser F, Parry A et al. Phase-II study of the new azaanthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematological 2003; 88(8): 888-894.
10. Borchmann P, Herbrecht R, Wilhelm M et al. Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2011; 52(4): 620-628.
11. Advani RH, Chen H, Habermann TM et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol 2010; 151(2): 143-151.
12. Nabhan C, Smith SM, Helenowski I et al. Analysis of very elderly (=80 years) non- Hodgkin's lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol 2012; 156(2): 196-204.